Compare YDES & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YDES | CGBD |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 906.2M |
| IPO Year | N/A | 2017 |
| Metric | YDES | CGBD |
|---|---|---|
| Price | $11.97 | $13.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.70 |
| AVG Volume (30 Days) | 110.9K | ★ 513.0K |
| Earning Date | 09-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 12.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | $510,360.00 | ★ $245,008,000.00 |
| Revenue This Year | N/A | $13.53 |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | ★ N/A | $11.45 |
| Revenue Growth | ★ 45.76 | 2.55 |
| 52 Week Low | $5.30 | $11.55 |
| 52 Week High | $31.00 | $18.64 |
| Indicator | YDES | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.76 |
| Support Level | N/A | $12.89 |
| Resistance Level | N/A | $12.26 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 85.31 |
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.